The LABORATORY Gazette Briefs

Servier and BioLabs launch a tender to join Spartners, the integrated incubator in the future Servier Research and Development Institute in Paris-Saclay

  • Spartners is a unique incubator in France that will offer all conditions to stimulate therapeutic innovation and promote knowledge sharing.
  • The call is open to start-ups in the field of health and life sciences to be among the first residents to join the incubator.

Servier and BioLabs Global announce the opening of the call for Spartners, the incubator integrated in the future Servier Research and Development Institute in Paris-Saclay, which will open its doors in 2023.
The call is aimed at young innovative companies in the field of health and life sciences that are developing innovative concepts. Companies can apply via the form accessible on the website

Applications will be examined by a selection committee composed of representatives of Servier and BioLabs, as well as expert personalities representing the main players in healthcare innovation: Medicen, France Biotech, the SATT network[1], and Bpifrance. Applicant companies can visit the incubator. For more information you can visit the site:

Spartners, a unique place in France to stimulate therapeutic innovation and knowledge sharing
Olivier Nosjean, Director of Open Innovation at Servier, says: “Spartners is the perfect reflection of the strong dynamic of open innovation led by Servier and his desire to have different healthcare professionals work together to accelerate the discovery of therapeutic solutions for the benefit We are happy to collaborate with BioLabs so that Spartners can be a place of synergies and innovation that will contribute to the dynamism of the healthcare ecosystem, in France and in Europe. ”
With an area of ​​1,850 m2, Spartners was designed to house around fifteen start-ups, or more than 100 scientists. The incubator will offer a unique combination in France of spaces distributed over four floors, state-of-the-art services and equipment that will allow start-ups to work independently while benefiting from Servier’s scientific and industrial expertise, as well as the world ecosystem of innovation. class of the Paris-Saclay cluster.

A partnership with BioLabs to maximize the chances of success for start-ups
BioLabs is an international network of coworking spaces designed to help science-based start-ups grow rapidly with limited capital investment. BioLabs will oversee the day-to-day management of the site, including the provision of services and equipment. Through the BioLabs network, residents will also have the opportunity to connect with entrepreneurs from around the world and corporate sponsors from a wide range of industries.
Servier and BioLabs share a common motivation: to detect and therefore support research projects that lead to therapeutic innovation.
Philippe Guédon, Director of the Spartners website, adds: “BioLabs’ motto is to enable a community of entrepreneurs to change the situation by accelerating the commercialization of their solution thanks to premium offerings (fully equipped turnkey laboratories, EH&S training, etc. .). In addition to BioLabs’ experience and know-how, our partnership with Servier allows our residents to benefit from a real industrial environment within Spartners, in order to further legitimize the science developed by start-ups. “
Johannes Fruehauf, CEO of BioLabs, said: “I am very happy to contribute together with Servier to the launch of Spartners. This new site will offer scientists and entrepreneurs the opportunity to benefit from our partnership with Servier, a world-leading pharmaceutical group, and to access BioLabs and our international network of shared laboratories. I am looking forward to meeting an amazing group of local, national and international entrepreneurs who will be conducting their research on this exceptional site. “

[1] Technology transfer acceleration company.

About Servier
Founded to serve health, Servier is an international pharmaceutical group governed by a foundation, which aspires to have a meaningful social impact for patients and a sustainable world. Her unique governance model enables her to fully serve her vocation with a long-term vision: to engage in therapeutic advancement for the benefit of patients. The 21,800 employees who make up the Group are committed to this common vocation, a source of daily inspiration.
A world leader in cardiology, Servier aims to become a recognized, targeted and innovative player in oncology by targeting difficult-to-treat cancers. For this reason, the Group dedicates more than 50% of its research and development budget to the development of targeted and innovative therapies in the oncology field.
Neuroscience and immune-inflammatory diseases are a future growth engine. In these areas Servier focuses on a limited number of specific pathologies in which a precise characterization of the patients allows to offer a targeted therapeutic response, thanks to precision medicine.
To promote access to quality care for all and at a lower cost, the Group also offers a range of generic medicines that cover most diseases, building on strong brands in France, Eastern Europe, Brazil and Nigeria.
In all these areas, the Group incorporates the patient’s voice at every stage of the drug’s life cycle.
Servier, headquartered in France, has a solid geographical presence in more than 150 countries and achieved a turnover of 4.7 billion euros in 2021.
More information on the new Group website:

About BioLabs
BioLabs designs and operates high-end life science labs and coworking spaces in the United States, Europe and Japan, in the heart of biotech innovation centers.
Thanks to the flexible conditions, the layout of their premises – in particular the fully equipped shared or private laboratory spaces and benefiting from a dedicated technical team, as well as the coworking spaces or private offices – BioLabs enables innovative companies in the science of the most promising lives to work, collaborate and organize events in an environment perfectly suited to your needs.
This fertile and supportive ecosystem allows novice companies to focus on innovation, not start-up operations, so they can quickly realize their scientific potential and achieve commercial success. Businesses can start with a single bank and scale as they grow.
More information on the site:

Split out :

Leave a Reply

Your email address will not be published. Required fields are marked *